Bright Minds Biosciences (DRUG) Total Liabilities (2019 - 2026)

Bright Minds Biosciences (DRUG) has 7 years of Total Liabilities data on file, last reported at $2.8 million in Q1 2026.

• Quarterly Total Liabilities rose 451.76% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (up 451.76% YoY) and the FY2025 annual result came in at $1.7 million, up 314.57% from the prior year.
• Total Liabilities rose to $2.8 million in Q1 2026, from $1.1 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $2.8 million in Q1 2026 to a low of $130602.2 in Q2 2024.
• A 5-year average of $770744.7 and a median of $547032.6 in 2023 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2023 — Total Liabilities slumped 82.31% — and 2026, when it soared 451.76%.
• Tracing DRUG's Total Liabilities over 5 years: stood at $429247.3 in 2022, then soared by 46.17% to $627410.9 in 2023, then tumbled by 34.78% to $409172.2 in 2024, then soared by 180.28% to $1.1 million in 2025, then surged by 143.7% to $2.8 million in 2026.
• The last three Total Liabilities figures came in at $2.8 million (Q1 2026), $1.1 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.